Medicus Pharma Files Rare Pediatric Disease Designation Request To FDA For SkinJect Microneedle Array Patch To Treat Basal Cell Carcinoma In Participants With Gorlin Syndrome

Medicus Pharma Ltd

Medicus Pharma Ltd

MDCX

0.00

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced the submission of a Rare Pediatric Disease Designation ("RPDD") request to the U.S. Food and Drug Administration ("FDA") for SkinJect®, the Company's investigational doxorubicin-containing microneedle array patch (D-MNA), for the treatment of basal cell carcinoma ("BCC") in patients with Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.